» Articles » PMID: 20634901

Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In Situ -Applications in Evaluating Novel Therapeutic Agents

Overview
Publisher Wiley
Date 2010 Jul 17
PMID 20634901
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial ovarian cancer (EOC) is the most commonly fatal gynecologic malignancy in developed countries. Most EOC patients are diagnosed at advanced stage when disease has spread beyond the ovary. While many patients initially respond to surgery and chemotherapy, the long term prognosis is generally unfavorable, with recurrence and development of drug resistant disease. There is a critical need to identify new therapeutic agents that prolong disease-free intervals and effectively manage recurrent disease. Murine models of ovarian carcinoma are excellent models to study tumor biology in the search for new treatments for EOC. Described in this unit are methods for establishing xenograft or allograft models of EOC using ovarian carcinoma cell lines, in vivo imaging strategies for detection and quantification of EOC in transgenic and in xenograft/allograft models, and procedures for necropsy and pathological evaluation of experimental animals.

Citing Articles

Reprogramming the tumor microenvironment leverages CD8 T cell responses to a shared tumor/self antigen in ovarian cancer.

Mistarz A, Winkler M, Battaglia S, Liu S, Hutson A, Rokita H Mol Ther Oncolytics. 2023; 28:230-248.

PMID: 36875325 PMC: 9982455. DOI: 10.1016/j.omto.2023.02.002.


Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling.

Sementino E, Kadariya Y, Cheung M, Menges C, Tan Y, Kukuyan A Mol Cancer Res. 2022; 20(5):699-711.

PMID: 35082167 PMC: 9081258. DOI: 10.1158/1541-7786.MCR-21-0837.


IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.

Yu C, Niu X, Du Y, Chen Y, Liu X, Xu L Cancer Immunol Immunother. 2019; 69(1):115-126.

PMID: 31802182 PMC: 11027837. DOI: 10.1007/s00262-019-02445-2.


The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-β/Smad signaling and induces apoptosis UCHL5 inhibition in ovarian cancer.

Fukui S, Nagasaka K, Miyagawa Y, Kikuchi-Koike R, Kawata Y, Kanda R Oncotarget. 2019; 10(57):5932-5948.

PMID: 31666925 PMC: 6800272. DOI: 10.18632/oncotarget.27219.


MUC16 as a novel target for cancer therapy.

Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker W Expert Opin Ther Targets. 2018; 22(8):675-686.

PMID: 29999426 PMC: 6300140. DOI: 10.1080/14728222.2018.1498845.


References
1.
Auersperg N, Maines-Bandiera S, Dyck H . Ovarian carcinogenesis and the biology of ovarian surface epithelium. J Cell Physiol. 1997; 173(2):261-5. DOI: 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G. View

2.
Kolfschoten G, Pinedo H, Scheffer P, Schluper H, Erkelens C, Boven E . Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system. Gynecol Oncol. 2000; 76(3):362-8. DOI: 10.1006/gyno.1999.5689. View

3.
Hensley H, Quinn B, Wolf R, Litwin S, Mabuchi S, Williams S . Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biol Ther. 2007; 6(11):1717-25. DOI: 10.4161/cbt.6.11.4830. View

4.
Sallinen H, Anttila M, Narvainen J, Orden M, Ropponen K, Kosma V . A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol. 2006; 103(1):315-20. DOI: 10.1016/j.ygyno.2006.03.030. View

5.
Kananen K, Markkula M, Rainio E, Su J, Hsueh A, Huhtaniemi I . Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene: characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines. Mol Endocrinol. 1995; 9(5):616-27. DOI: 10.1210/mend.9.5.7565808. View